Other notable targets being investigated in the STS realm include NTRK fusion in CD34-positive fibrosarcomas of bone and soft tissue [101,102,103], EZH2/INI1 loss (epithelioid sarcomas, rhabdoid tumors) [104], and ALK fusion in inflammatory myofibroblastic tumors [105]. This evidence concerns the gene ALK and epithelioid sarcoma.